DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease - Trial NCT06230562
Access comprehensive clinical trial information for NCT06230562 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Tours and is currently Not yet recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Tours
Timeline & Enrollment
N/A
Feb 01, 2024
Aug 01, 2025
Primary Outcome
Presence of TDP-43 aggregates in PBMC,PBMC accompanied by a protein expression profile under Nrf-2 control
Summary
In response to oxidative stress, cells activate the Nrf-2 pathway, which induces translation
 of its target genes and corresponding proteins involved in the antioxidant response. This
 explains the interest in the Nrf-2 pathway in the pathophysiology of Amyotrophic lateral
 sclerosis (ALS), supported by the results of several studies and the modulatory effect of
 TDP-43 on the Nrf-2 pathway. Since both TDP-43 and Nrf-2 proteins are present in the
 peripheral blood mononuclear cells (PBMC) of ALS patients and may be correlated with disease
 progression, the investigators wish to explore their relationship and their application in
 the clinic as potential blood biomarkers for ALS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06230562
Non-Device Trial